Industry News

Resverlogix Corp. today announced that on Sunday, August 28, 2016, at the European Society of Cardiology Congress in Rome, Italy, the Company hosted a symposium entitled "A novel approach for high CV risk patients with diabetes: The potential of epigenetics.""/>
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy
HemaCare sponsors CAR-TCR Summit in support of researchers developing cell therapies utilizing T-cell receptor modifications. LOS ANGELES---- HemaCare Corporation, a leader in cell and tissue collection, processing, and cell therapy solutions, today announced that it is supporting the 2016 CAR-TCR Summit to be hosted at the Hyatt Regency in Boston September 13-15 th. This summit is the premiere meeting attended by 400 scientific and clinical leaders working on the..."/>
HemaCare Supports 2016 CAR-TCR Summit
IMS Health Holdings, Inc. and contract research provider Quintiles Transnational Holdings Inc. have determined key senior management roles in the future Quintiles IMS corporate leadership team, subject to the completion of the merger, the companies said. Senior functional leaders reporting to chairman and chief executive officer Ari Bousbib will include EVP and chief financial officer..."/>
IMS Health and Quintiles Name Key Officers for Merged Firm
Nymox Pharmaceutical Corporation lead drug fexapotide which has been in development for over a decade and which has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers throughout the US, has been found after 7 years of prospective placebo controlled double blind studies of treatment of 995 U.S...."/>
Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show 
BioTelemetry, Inc., the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce that the Company has received CE mark approval of its Holter analysis software. The software can be used either on a stand-alone basis or in combination with the Company’ s family of digital Holter recorders.. Joseph H. Capper, President and Chief Executive Officer of..."/>
BioTelemetry, Inc. announces CE mark approval of Holter analysis software
Universal Health Services, Inc., including the Issuer Default Rating at' BB+' and the senior secured credit facility and senior secured bond ratings at' BBB-/RR1'. The Rating Outlook is Stable. A full list of rating actions, which apply to approximately $3.6 billion of debt outstanding at June 30, 2016, is found at the end of this release."/>
Fitch Affirms Universal Health Services at 'BB+'; Outlook Stable
Omnicell, Inc., a leading provider of medication automation, supply management and medication adherence solutions for healthcare settings, will visit the Nasdaq MarketSite in Times Square. In honor of Omnicell’ s 15th Nasdaq Listing Anniversary, Randall A. Lipps, Chairman, President, Chief Executive Officer, and Founder, will ring the Opening Bell. Where: Nasdaq MarketSite– 4 Times Square– 43 rd& Broadway– Broadcast Studio."/>
Omnicell, Inc. (Nasdaq: OMCL) to Ring The Nasdaq Stock Market Opening Bell
Cigna is introducing additional and more flexible health plan choices for mid- and smaller-sized employers through its enhanced Cigna Guided Solutions ® benefit technology platform, initially launched in 2014.. In addition to Cigna's broad array of pre-configured medical, dental, vision and group life, disability and accident insurance, and other benefit plans, Cigna's state of the art benefit technology solution now..."/>
Cigna Guided Solutions Now Offers Midsize and Smaller Employers More Options and Flexibility
Ekso Bionics Holdings, Inc., a robotic exoskeleton company, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Tom Lobby, President and CEO, will ring the Closing Bell. Where: Nasdaq MarketSite– 4 Times Square– 43 rd& Broadway– Broadcast Studio."/>
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) to Ring The Nasdaq Stock Market Closing Bell
pSivida Corp., a leader in the development of sustained release drug delivery products primarily for eye diseases, announced the addition of 13 U.S. and foreign issued patents and allowed applications since the start of 2016. This brings the total number of patents issued and applications allowed in the Company’ s intellectual property portfolio to 42 in the U.S. and 191 in foreign jurisdictions. An additional 108 applications are pending in the U.S...."/>
PSivida Announces 13 New Patents Issued or Allowed
KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced the sale by Martin Shkreli of his remaining shares of KaloBios common stock, fully eliminating his association with the company. KaloBios also outlined its..."/>
KaloBios Announces Martin Shkreli’s Sale of His Stake in the Company
Cerecor Inc., a biopharmaceutical company developing innovative drugs that have the potential to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that Dr. Sherry McKee from Yale University has enrolled the first subject in the Phase 2 clinical trial for CERC-501,“ Does CERC-501 Attenuate Stress-Related Smoking Lapse?"/>
Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in Smokers
MorphoSys AG will present at the following conferences:. Commerzbank Sector Conference 2016 Date: August 30, 2016 Venue: Frankfurt, Germany Presenter: Jens Holstein, Chief Financial Officer of MorphoSys AG; Dr. Claudia Gutjahr-Löser, Head of Corporate Communications& IR Goldman Sachs Annual Biotech Symposium Date: September 9, 2016 Venue: London, UK Presenter: Dr."/>
MorphoSys to Present at Upcoming Investor Conferences
MetaStat, Inc., a molecular diagnostic company, today announced the company will present clinical data and results from two studies at the San Antonio Breast Cancer Symposium, taking place December 6-10, 2016 at the Henry B. Gonzalez Convention Center in San Antonio, TX. “We are pleased to have two of our studies involving MetaSite Breast™ accepted for presentation at this year’ s San Antonio Breast Cancer Symposium, including an oral presentation by Dr."/>
MetaStat Announces Presentation of Two MetaSite Breast™ Studies at the 2016 San Antonio Breast Cancer Symposium
Ossur Hf : Össur - Share options granted
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced it has entered into a Development and License Agreement with SunGen Pharma, LLC to collaborate to develop and commercialize four generic pharmaceutical products.. Under the terms of the agreement, Elite and SunGen will share in the responsibilities and costs in the development of the products."/>
Elite Announces Development and License Agreement with SunGen Pharma LLC
Titan Medical Inc., a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery, today announced that Dr. Dennis Fowler will resign from Titan effective August 31, 2016. Dr. Fowler has been with Titan since March 2014, most recently as Executive Vice President of Clinical and Regulatory Affairs."/>
Titan Medical Inc. Corporate Update
Amgen today announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind, double-dummy, active-controlled study evaluating the safety and efficacy of Prolia ® compared with risedronate in patients receiving glucocorticoid treatment. The study met all primary and secondary endpoints at 12 months. The data showed that treatment with Prolia for 12 months, compared to risedronate,..."/>
Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia® (Denosumab) In Patients Receiving Glucocorticoid Therapy
EP Global Communications, Inc. announces today that it has been notified of an allowance from the United States Patent& Trademark Office on its first patent, US 14/ 668,957 "System for Contact Lens Wireless Communication." With this allowance, EPGL now has several patents pending in the new field of "smart contact lenses" and "augmented vision" technology. EPGL's technologies have attracted the attention of major industry players and in April of..."/>
EPGL Wins Allowance on First Patent
CEL-SCI Corporation announced that it has closed its previously announced registered direct offering with institutional investors. The Company has received gross proceeds of $5 million. Rodman& Renshaw, a unit of H.C."/>
CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering
Kadmon Holdings, Inc. today announced that the first patient has been dosed in a Phase 2 clinical trial of tesevatinib, the Company’ s oral tyrosine kinase inhibitor, for the treatment of recurrent glioblastoma. The open-label, multicenter study examines tesevatinib monotherapy administered at 300 mg once daily in up to 40 patients in the United States. Tesevatinib is an oral inhibitor of epidermal growth factor receptor, a cell surface receptor whose gene is amplified..."/>
Kadmon Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Glioblastoma
Macrocure Ltd. today announced the signing of a definitive merger agreement. Under the terms of the agreement, Macrocure will become a wholly owned subsidiary of Leap, and Leap will become a public company."/>
Leap Therapeutics and Macrocure Announce Definitive Merger Agreement

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary533 Articles
Information Technology468 Articles
Financials407 Articles
Industrials277 Articles
Health Care274 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at